Creatv Bio and Neovia Oncology Forge Partnership to Combat Drug Resistance in Solid Tumors
Creatv Bio, a division of Creatv MicroTech, known for its developments in liquid biopsy technologies, has recently entered a significant collaborative agreement with Neovia Oncology, a Delaware-based pharmaceutical company. This strategic partnership aims to tackle the challenges posed by multiple drug-resistant solid tumors—cancers that resist many chemotherapy options—by enhancing patient treatment strategies through innovative research practices.
The partnership's primary focus is on Neovia's ongoing clinical studies, which aim to treat patients suffering from advanced multiple drug resistant solid tumors that are often at the end of their treatment options. By aligning their expertise, both companies seek to generate vital translational and biomarker data, which is expected to enhance patient stratification—a process that tailors treatment strategies to individual patient profiles—and to deepen the understanding of how cancer treatments respond in advanced cancer cases.
"Selecting Creatv Bio was a strategic decision based on their exceptional scientific prowess and their broad experience in supporting biomarker research across various solid tumor types," shared Trevor Blake, the Founder and CEO of Neovia Oncology. He elaborated on the integration of liquid biopsy technologies into Neovia's clinical development program, hoping to extract deeper insights into how patients respond to treatments and to comprehend the biology behind treatment resistance as NEV-801 advances through the stages of clinical trials.
Creatv Bio employs advanced blood testing techniques through its proprietary LifeTracDx® test, which isolates Cancer Associated Macrophage-Like Cells (CAMLs) and Circulating Tumor Cells (CTCs). These technologies rely on Creatv's innovative CellSieveTM microfilters, designed to develop companion diagnostics that will not only monitor drug targets but also provide actionable insights on how patients are responding to treatments.
The implications of this partnership are immense. Dr. Cha-Mei Tang, President and CEO of Creatv Bio, expressed optimism about their collaboration with Neovia, asserting that it has the potential to significantly advance cancer diagnosis and treatment methods. Such advancements could lead to improved outcomes and quality of life for cancer patients facing daunting challenges with treatment-resistant tumors.
About Creatv Bio: Creatv Bio operates a CLIA-certified laboratory focusing on cancer diagnostics and supports pharmaceutical partners with both research and investigational studies. Notably, its LifeTracDx® tests have been analytically validated, although they are currently designated for research and development rather than clinical diagnostics.
About Neovia Oncology LLC: Neovia is a clinical-stage oncology company dedicated to developing therapies aimed at overcoming the challenges faced by current cancer treatments, particularly those associated with treatment resistance and tolerability. Their lead investigational candidate, NEV-801, is being examined for its potential across a range of advanced solid tumors, which places the company at the forefront of developing novel therapeutic strategies in oncology.
In conclusion, the partnership between Creatv Bio and Neovia Oncology represents a significant step toward enhancing the understanding and treatment of resistant solid tumors, combining cutting-edge diagnostic technology with innovative therapeutic strategies. As they embark on this ambitious journey, the potential to improve the lives of cancer patients is an encouraging prospect for the medical community and patients alike.
The partnership's primary focus is on Neovia's ongoing clinical studies, which aim to treat patients suffering from advanced multiple drug resistant solid tumors that are often at the end of their treatment options. By aligning their expertise, both companies seek to generate vital translational and biomarker data, which is expected to enhance patient stratification—a process that tailors treatment strategies to individual patient profiles—and to deepen the understanding of how cancer treatments respond in advanced cancer cases.
"Selecting Creatv Bio was a strategic decision based on their exceptional scientific prowess and their broad experience in supporting biomarker research across various solid tumor types," shared Trevor Blake, the Founder and CEO of Neovia Oncology. He elaborated on the integration of liquid biopsy technologies into Neovia's clinical development program, hoping to extract deeper insights into how patients respond to treatments and to comprehend the biology behind treatment resistance as NEV-801 advances through the stages of clinical trials.
Creatv Bio employs advanced blood testing techniques through its proprietary LifeTracDx® test, which isolates Cancer Associated Macrophage-Like Cells (CAMLs) and Circulating Tumor Cells (CTCs). These technologies rely on Creatv's innovative CellSieveTM microfilters, designed to develop companion diagnostics that will not only monitor drug targets but also provide actionable insights on how patients are responding to treatments.
The implications of this partnership are immense. Dr. Cha-Mei Tang, President and CEO of Creatv Bio, expressed optimism about their collaboration with Neovia, asserting that it has the potential to significantly advance cancer diagnosis and treatment methods. Such advancements could lead to improved outcomes and quality of life for cancer patients facing daunting challenges with treatment-resistant tumors.
About Creatv Bio: Creatv Bio operates a CLIA-certified laboratory focusing on cancer diagnostics and supports pharmaceutical partners with both research and investigational studies. Notably, its LifeTracDx® tests have been analytically validated, although they are currently designated for research and development rather than clinical diagnostics.
About Neovia Oncology LLC: Neovia is a clinical-stage oncology company dedicated to developing therapies aimed at overcoming the challenges faced by current cancer treatments, particularly those associated with treatment resistance and tolerability. Their lead investigational candidate, NEV-801, is being examined for its potential across a range of advanced solid tumors, which places the company at the forefront of developing novel therapeutic strategies in oncology.
In conclusion, the partnership between Creatv Bio and Neovia Oncology represents a significant step toward enhancing the understanding and treatment of resistant solid tumors, combining cutting-edge diagnostic technology with innovative therapeutic strategies. As they embark on this ambitious journey, the potential to improve the lives of cancer patients is an encouraging prospect for the medical community and patients alike.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.